Commentary: Takeda/Alnylam Best Alliance Deal Of 2008?
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals' May collaboration with U.S.-based Alnylam and its RNAi work was one of the best deals in that class of drugs in 2008. The move even topped Takeda's alliance with Amgen and acquisition of Millennium, both of the United States, earlier in the year. The Anylam alliance also could help the American company gain access to candidate drugs under development by other drug makers and even obtain a partner for its RNAi work elsewhere in Asia. All of that is in addition to the alliance's arrangement for Alnylam to share in marketing rights for up to four Takeda programs of Alnylam's choosing. It also allows Alnylam to finish the year with $500 million during a global financial crisis. (Click here for more
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.